Holzer & Holzer, LLC is investigating whether Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") (NASDAQ: TTPH) complied with the federal securities laws. On February 13, 2018, Tetraphase announced that its IGNITE3 clinical trial did not achieve its co-primary endpoints of responder rate at the end of treatment and test-of-cure visit. The price of Tetraphase stock fell significantly following the announcement.

If you purchased Tetraphase common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at cholzer@holzerlaw.com or Alexandria P. Rankin, Esq. at arankin@holzerlaw.com, or call the firm by toll-free telephone at (888) 508-6832.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180214006086/en/

Copyright Business Wire 2010